Argentina approves higher-dose semaglutide for medical weight loss

Argentina's regulator approved a 7.2 mg dose of semaglutide for patients requiring greater medically-indicated weight loss. The approval expands treatment options but raises questions about efficacy, tolerance, and muscle preservation at higher doses. This is a regulatory decision with potential public-health implications, though market impact is limited.